Could MS patients switch to once-yearly infusions? new trial aims to find out
NCT ID NCT05999604
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 trial tests whether people with active multiple sclerosis who have been stable on Ocrevus for at least two years can safely switch to annual infusions instead of the standard every-6-month schedule. The goal is to see if the less frequent dosing is just as good at preventing new brain lesions, while potentially lowering infection risk and reducing hospital visits. About 244 adults will be randomly assigned to receive Ocrevus either once or twice a year for two years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ocrelizumab (Ocrevus)
What this could lead to
If successful, this could allow people with stable MS to receive infusions once a year instead of twice, reducing infection risk and treatment burden.
What could go wrong
This is a non-inferiority trial, so it may show that annual dosing is slightly less effective at preventing new brain lesions. The study is also relatively small (244 people) and only follows participants for two years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CH Gonesse
RECRUITINGGonesse, 95500, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
CHI Poissy-Saint-Germain en Laye
RECRUITINGPoissy, 78300, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
CHU de Grenoble
RECRUITINGGrenoble, 38043, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
CHU de Limoges
RECRUITINGLimoges, 87042, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
CHU de Nice
RECRUITINGNice, 06000, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
CHU de Strasbourg
RECRUITINGStrasbourg, 67098, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Fondation Adolphe de Rothschild
RECRUITINGParis, 75019, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Hôpital Foch
RECRUITINGSuresnes, 92150, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Hôpital Henri Mondor
RECRUITINGCréteil, 94010, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Hôpital Pierre Wertheimer (HCL)
RECRUITINGLyon, 69500, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Hôpital de la Pitié-Salpêtrière
RECRUITINGParis, 75013, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact